Zur Verstärkung unseres Teams in Berlin suchen wir ab sofort einen

Personalsachbearbeiter (w/m) in Teilzeit

Ihre wichtigsten Aufgaben in der Personalverwaltung

• Bewerber- und Terminmanagement
• Melde- und Bescheinigungswesen
• Erfassung der Mitarbeiterdaten im Zeiterfassungssystem
• Führung der Personalakten und Pflege der Stammdaten
• Betreuung der monatlichen Abrechnung
• Unterstützung bei internen Projekten

In Ihrer Funktion unterstützen Sie die Personalreferentin im Tagesgeschäft. Sie sind Ansprechsprechpartner für personalrelevante Fragen für unsere Standorte Berlin und Heidelberg.

Ihre Qualifikationen

• Erfolgreich abgeschlossenes kaufmännische Berufsausbildung eventuell mit Zusatzqualifikation zur /zum Personalkauffrau /-kaufmann
• Berufserfahrung in einer vergleichbaren Position sind erwünscht
• Gute Englischkenntnisse in Wort und Schrift
• Strukturierte und genaue Arbeitsweise
• Loyalität, Diskretion und Organisationstalent

Teamfähigkeit, Flexibilität, Zuverlässigkeit und selbständige Arbeitsweise runden Ihr Profil ab.

Begründet in unserer Firmenphilosophie geben wir Familienfrauen/-männern gerne die Chance eines Wiedereinstiegs.

Wir freuen uns auf Ihre Bewerbung bei:

GLYCOTOPE GmbH
Bettina Eichhöfer
Robert-Roessle-Str. 10
13125 Berlin

Tel.: +49-30-9489-2604
Fax : +49-30-9489-2609
e-mail: bettina.eichhoefer@glycotope.com

Wir expandieren und suchen zum sofortigen Eintritt für unsere biotechnologische Produktion im Bereich Zellkultur / Upstream Processing (USP) eine(n)

Dipl. Ingenieur (FH), Master, Dipl. Biol. Biotechnologie/Biochemie (w/m)

Ihre wichtigsten Aufgaben

• Kultivierung von Säugerzelllinien mit dem Ziel der GMP-gerechten Herstellung rekombinanter Proteinwirkstoffe
• Betreuung von Zellkulturentwicklungsprojekten
• Bedienung von Bioreaktoren
• Wartungs- und Kalibrierungsarbeiten
• Gerätequalifizierungen und Prozessvalidierungen

Ihre Qualifikationen

• Abgeschlossene Ausbildung als Dipl. Ing. (FH) Biotechnologie (w/m)
• Erfahrung in der Aufreinigung von Proteinen/Antikörpern aus Zellkulturüberständen
• Erfahrung in der Bedienung und Überwachung von Filtrations- und Chromatographie-Anlagen
• Erfahrung in sterilen Arbeitstechniken
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen
• Sorgfältige Dokumentation der Arbeit
• Erstellen von Herstellvorschriften (SOPs)
• GMP-Kenntnisse sind von Vorteil
• Fähigkeit zur flexiblen Teamarbeit
• Zuverlässige und verantwortungsbewusste Arbeitsweise
• Geübter Umgang mit gängigen Computerprogrammen (MS Office)
• Gute Englischkenntnisse
• Kenntnisse im Umgang mit Qualitätsmanagementsystemen wünschenswert

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

Wir expandieren und suchen zum sofortigen Eintritt für unsere biotechnologische Produktion im Bereich Formulierung und Abfüllung (FIL) eine(n)

Pharmatechniker/in

Ihre wichtigsten Aufgaben

• Formulierung und Abfüllung von Wirkstoffen im Rahmen der biotechnologischen Produktion
• Herstellung von aseptischen Arzneimittel (sterile Abfüllungen)
• Mitarbeit bei der Überwachung von Arzneimittelbeständen
• Wartungs- und Kalibrierungsarbeiten
• Gerätequalifizierungen und Prozessvalidierungen

Ihre Qualifikationen

• Abgeschlossene Berufsausbildung als PTA oder ähnlicher Fachrichtung
• Erfahrung in sterilen Arbeitstechniken
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen
• Sorgfältige Dokumentation der Arbeit
• Erstellen von Herstellvorschriften (SOPs)
• GMP-Kenntnisse sind von Vorteil
• Fähigkeit zur flexiblen Teamarbeit
• Zuverlässige und verantwortungsbewusste Arbeitsweise
• Geübter Umgang mit gängigen Computerprogrammen (MS Office)
• Englischkenntnisse vorteilhaft
• Kenntnisse im Umgang mit Qualitätsmanagementsystemen wünschenswert

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

Wir expandieren und suchen zum sofortigen Eintritt für unsere biotechnologische Produktion im Bereich Down Stream Processing (DSP) eine(n)

Biotechniker/in

Ihre wichtigsten Aufgaben

• Entwicklung und Optimierung von Aufreinigungsprozessen rekombinanter Proteine/Antikörper aus Zellkulturüberständen im Rahmen der biotechnologischen Wirkstoff-Produktion (Down Stream Processing)
• Etablierung neuer Aufreinigungsverfahren
• Wartungs- und Kalibrierungsarbeiten
• Gerätequalifizierungen und Prozessvalidierungen

Ihre Qualifikationen

• Abgeschlossene Berufsausbildung als BTA, CTA, PTA oder ähnlicher Fachrichtung
• Erfahrung in sterilen Arbeitstechniken
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen
• Sorgfältige Dokumentation der Arbeit
• Erstellen von Herstellvorschriften (SOPs)
• GMP-Kenntnisse sind von Vorteil
• Fähigkeit zur flexiblen Teamarbeit
• Zuverlässige und verantwortungsbewusste Arbeitsweise
• Geübter Umgang mit gängigen Computerprogrammen (MS Office)
• Englischkenntnisse vorteilhaft
• Kenntnisse im Umgang mit Qualitätsmanagementsystemen wünschenswert

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

Wir expandieren und suchen zum sofortigen Eintritt für unsere biotechnologische Produktion im Bereich Down Stream Processing (DSP) eine(n)

Dipl. Ingenieur (FH), Master, Dipl. Biol. Biotechnologie/Biochemie (w/m)

Ihre wichtigsten Aufgaben

• Entwicklung und Optimierung von Aufreinigungsprozessen rekombinanter Proteine/Antikörper aus Zellkulturüberständen im Rahmen der biotechnologischen Wirkstoff-Produktion (Down Stream Processing)
• Etablierung neuer Aufreinigungsverfahren
• Wartungs- und Kalibrierungsarbeiten
• Gerätequalifizierungen und Prozessvalidierungen

Ihre Qualifikationen

• Abgeschlossene Ausbildung als Dipl. Ing. (FH) Biotechnologie (w/m)
• Erfahrung in der Aufreinigung von Proteinen/Antikörpern aus Zellkulturüberständen
• Erfahrung in der Bedienung und Überwachung von Filtrations- und Chromatographie-Anlagen
• Erfahrung in sterilen Arbeitstechniken
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen
• Sorgfältige Dokumentation der Arbeit
• Erstellen von Herstellvorschriften (SOPs)
• GMP-Kenntnisse sind von Vorteil
• Fähigkeit zur flexiblen Teamarbeit
• Zuverlässige und verantwortungsbewusste Arbeitsweise
• Geübter Umgang mit gängigen Computerprogrammen (MS Office)
• Gute Englischkenntnisse
• Kenntnisse im Umgang mit Qualitätsmanagementsystemen wünschenswert

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

Wir expandieren und suchen zum sofortigen Eintritt für unseren biotechnologische Produktion im Bereich Zellkultur / Upstream Processing (USP) eine(n)

Biotechniker/in

Ihre wichtigsten Aufgaben

• Kultivierung von Säugerzelllinien mit dem Ziel der GMP-gerechten Herstellung rekombinanter Proteinwirkstoffe
• Mitarbeit an Zellkulturentwicklungsprojekten
• Bedienung von Bioreaktoren
• Wartungs- und Kalibrierungsarbeiten
• Gerätequalifizierungen und Prozessvalidierungen

Ihre Qualifikationen

• Abgeschlossene Berufsausbildung als BTA, CTA, PTA oder ähnlicher Fachrichtung
• Erfahrung in sterilen Arbeitstechniken
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen
• sorgfältige Dokumentation der Arbeit
• Erstellen von Herstellvorschriften (SOPs)
• GMP-Kenntnisse sind von Vorteil
• Fähigkeit zur flexiblen Teamarbeit
• Zuverlässige und verantwortungsbewusste Arbeitsweise
• Geübter Umgang mit gängigen Computerprogrammen (MS Office)
• Englischkenntnisse vorteilhaft
• Kenntnisse im Umgang mit Qualitätsmanagementsystemen wünschenswert

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

About Glycotope:

GLYCOTOPE, founded in 2001 in Berlin, focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. Biologics developed in Glycotope´s GlycoExpress^TM technology of glycoengineered human cell lines receive a fully human and optimized glycosylation, leading to a largely improved activity, an elongated half-life time and/or reduced immunogenicity and hence important therapeutic benefits for a significantly increased number of patients. In addition, the GlycoExpress platform is superior in productions yields, product quality and reproducibility compared to other production platforms.

Glycotope´s product portfolio now encompasses a variety of antibodies and non-antibody biologics, 4 of which are currently in the clinical stage. This pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters.

Together with Glycotope-Biotechnology in Heidelberg, Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development such as lead discovery and optimization, preclinical and process development, GMP production and clinical development. With more than 140 employees, the group has grown to one of the largest Biotech organisations in Germany.

About the CPhI Innovation Award

The internationally acclaimed CPhI Innovation Awards were established to recognise, celebrate and honour those companies and organisations that are breaking new ground in the pharmaceutical, contract services, packaging and biopharmaceutical. Entry categories are open to all exhibitors at the events and were expanded to reflect the zoned layout of the 2011 events. Submissions were accepted from the following areas: APIs, Custom Manufacturing, Intermediates, Excipients/Formulation, Fine Chemicals, Finished Dosage, Contract Services, Drug Delivery Systems and Biopharmaceuticals. When choosing the finalists, the judges looked for the innovations that encouraged the imagination and are commercially practical.

Wir expandieren und suchen zum sofortigen Eintritt für unseren Geschäftsbereich Biotechnologische Produktion im Bereich Upstream Stream Processing (USP) eine(n)

Dipl. Ingenieur (FH), Master, Dipl. Biol. USP (w/m)

Aufgabengebiet

• Kultivierung von Säugerzelllinien im Rahmen von Entwicklungsprojekten
• Erstellen von Zellbänken
• Erstellung von Plänen und Berichten zu den Versuchsreihen
• Qualifizierung und Instandhaltung von Geräten
• GMP-gerechte Dokumentation
• Bereitschaft zu Wochenenddiensten

Anforderungsprofil

• Abgeschlossene Ausbildung als Dipl. Ingenieur (FH), Master, Dipl. Biol. (w/m)
• Erfahrung mit Zellkulturtechniken, auch im größeren Maßstab
• Erfahrung in sterilen Arbeitstechniken
• Selbstständiges Vorbereiten, Planen und Arbeiten
• Erstellen von Herstell-/Arbeitsvorschriften (SOPs)
• Sorgfältige Dokumentation der Arbeit
• Bereitschaft zu Wochenendarbeit
• Erfahrung mit Arbeiten in pharmazeutischen Reinräumen sind von Vorteil
• GMP-Kenntnisse sind von Vorteil
• Gute Englisch-Kenntnisse
• Gute Kenntnisse in den gängigen Computer-Programmen
• Erfahrung in der Anleitung technischen Personals von Vorteil
• Teamfähigkeit

Unser Angebot

• Unbefristeter Arbeitsplatz
• Vollzeit
• Flexible Arbeitszeiten
• Abwechslungsreiche Tätigkeit in einem innovativen Unternehmen
• Junges, kollegiales Arbeitsumfeld

Als Mitglied eines engagierten Teams motiviert Sie eine interessante und abwechslungsreiche Tätigkeit. Sie schätzen Herausforderungen und selbständiges Arbeiten. Ihre Ergebnisse protokollieren Sie klar und übersichtlich. Es erwartet Sie ein innovatives Umfeld mit guten beruflichen Entwicklungsmöglichkeiten.

Wir freuen uns darauf, Sie näher kennen zu lernen. Bitte richten Sie Ihre ausführliche, schriftliche Bewerbung in elektronischer Form, mit Angabe Ihres möglichen Eintrittstermins und Ihrer Gehaltsvorstellung an Frau Bettina Eichhöfer

Glycotope Biotechnology GmbH│Czernyring 22│69115 Heidelberg│Tel. 06221/9105-0│E-Mail: humanresources@glycotope-bt.com│www.glycotope-bt.com

Booths #1456 & #1458 ( Floor Plan BIO 2012)

“We are delighted to see our 4th glycooptimized biopharmaceutical product in clinical trials”, says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. “After CetuGEX™ and PankoMab-GEX™, TrasGEX is our 3rd anti-cancer antibody which entered clinical trials in time. GlycoExpress has been proven to be the broadest glycooptimization technology not only for antibodies but also for most other glycoproteins. Our glycooptimized Follicle-Stimulating Hormone FSH-GEX™ has already completed clinical phase Ia with very exciting results. Currently we are advancing a broad range of pre-clinical products in various therapeutic areas”.

About Glycotope
GLYCOTOPE, founded in 2001 in Berlin, focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. Biologics developed in Glycotope´s GlycoExpress™ technology of glycoengineered human cell lines receive a fully human and optimized glycosylation, leading to a largely improved activity, an elongated half-life time and/or reduced immunogenicity and hence important therapeutic benefits for a significantly increased number of patients. In addition, the GlycoExpress platform is superior in productions yields, product quality and reproducibility compared to other production platforms.

Glycotope´s product portfolio now encompasses a variety of antibodies and non-antibody biologics, 4 of which are currently in the clinical stage. This pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters.

Together with Glycotope-Biotechnology in Heidelberg, Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development such as lead discovery and optimization, preclinical and process development, GMP production and clinical development. With more than 140 employees, the group has grown to one of the largest Biotech organizations in Germany.

Based on GlycoExpress™, Glycotope´s development and production platform of glycoengineered human cell lines, FSH-GEX™ combines into one single product the safety advantages of a recombinant origin with the fully human nature of pharmaceuticals derived from urinary sources plus the glycooptimization of the molecule.

“After having 2 antibodies in clinical trials and a third antibody approved by the competent authority, starting the clinical phase for FSH-GEX™ is an important milestone for the company, as it is our first glycooptimized non-antibody product in the clinic, validating the broad applicability of GlycoExpress™ to not just antibodies but almost all glycosylated proteins”, states Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope. “In addition, we are expecting that the first patients for TrasGEX™, our glycooptimized Trastuzumab, will be enrolled within the next weeks. We then will have successfully completed our ambitious plans to bring four glycooptimized biopharmaceuticals into the clinic within a very short time”.

About Glycotope
GLYCOTOPE, founded in 2001 in Berlin, focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. Biologics developed in Glycotope´s GlycoExpress™ technology of glycoengineered human cell lines receive a fully human and optimized glycosylation, leading to a largely improved activity, an elongated half-life time and reduced immunogenicity and hence important therapeutic benefits for a significantly increased number of patients. In addition, the GlycoExpress platform is superior in productions yields, product quality and reproducibility compared to other production platforms.

Glycotope´s product portfolio now encompasses a variety of antibodies and non-antibody biologics, 4 of which are currently in the clinical stage. This pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters.

Together with Glycotope-Biotechnology in Heidelberg, Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development such as lead discovery and optimization, preclinical and process development, GMP production and clinical development. With more than 140 employees, the group has grown to one of the largest Biotech organisations in Germany.

Contact:

Glycotope GmbH
Dr. Franzpeter Bracht, CFO & CBO
Robert-Roessle-Str. 10
13125 BERLIN
Germany
Tel. +49 (0)30 94 89-2600
Fax: +49 (0)30 94 89-2609
franzpeter.bracht@glycotope.com

We offer a range of teramers to monitor T cell response in

• Infectious diesease
• Cancer Research
• Vaccine development
• Transplantation immunology

On request we manufacture

• Tetramers with peptides of your choice
• Biotinylated monomers
• Synthetic peptides
• PE-or APC-labeled Tetramers

Pricelist (PDF, 872 KB)

Custom MHC-Tetramer Synthesis Service

www.glycotope-bt.com – Class One Tetramer Reagents
All tetramers are also available with FITC-labeled anti- CD8 monoclonal antibodies. We supply MHC-peptide complexes as PE-labeled tetramers available in 50 and 100 test quantities
Biotinylated MHC-Peptide Monomers for magnetic isolation of antigen-specific T cells

Custom Peptide Synthesis

Lyophilized peptides available in 1 to 10 mg quantities with 90 % purity
We also provide you with excellent technical service if you have any ques- tions regarding MHC-technology and staining protocols.

Step 1: Assessment of absolute CD8+ T cell counts using counting beads

1. Addition of antibodies

2. Addition of whole blood

3. Lyse – no wash

FL3 (CD3-PerCp) versus SSC dot plot. Set region on CD3+ T-Lymphocytes (R1). Set threshold on FL3 to minimize debris

Step 1:

Dot plot setup for assessment of absolute CD8T cell counts using counting beads

Ungated CD4 versus CD8 dot plot. Set gate on counting beads (R2)

R1 gated T-lymphocytes. Set CD8 (R3) and CD4 (R4)

Data Evaluation

(1) Calculating absolute counts of CD8 T-lymphocytes: Determine the number of CD8+ T-lymphocytes in region 3 and the number of counting beads in region 2.

If you are not using a BD software program that automatically calculates absolute cell counts, you can perform a manual calculation using the following equation:

*This value is found on the TruCOUNT Absolute Count Tube foil pouch label

Step 2: Assessment of % Tetramer binding T-lymphocytes

1. Addition of whole blood

2. Addition of Tetramer

3. Addition of CD3 and CD8

4. Lyse – wash

Ungated SSC versus CD3-PerCP (FL3). Set region on CD3+ lymphocytes (R5)

Step 2:

Dot plot setup for assessment of % Tetramer binding T-lymphocytes

Fig 1: R5 gated CD8-FITC versus Tetramer-PE. Set region on all CD8 cells (R6) and on Tetramer counts (R7)

Fig 2: R5 gated CD8-FITC versus negative Tetramer-PE. Copy R6 and R7 and paste into dot plot.

Data Evaluation

(2) Determining the percentage of Tetramer positive CD8+ T-lymphocytes: After setting a region on CD3+ T-lymphocytes (R5), the percentage of Tetramer+/CD8+ T-lymphocytes is determined in R6 in figure 1 (positve Tetramer) and figure 2 (negative Tetramer)

(Absolute Count of CD3+CD8+ cells) x (Tetramer-positive events as a percent of CD8+ cells /100 = CD3+CD8+ Tetramer+ cells per ml whole blood

Handling (PDF, 954 KB)

The delighted Dr. Steffen Goletz, founder and CEO of Glycotope GmbH comments: “In particular the expansion of our DSP (Downstream Processing) capacities now places us among the top providers of GMP-production for recombinant proteins and in particular antibodies in Germany”.

About Glycotope and GlycotopeBiotechnology:

Glycotope-Biotechnology, a full subsidiary of Berlin based Glycotope GmbH was founded upon the acquisition of the GMP-production unit of former Orpegen Pharma GmbH, together with the transfer of manufacturing lines of former Avesta GmbH in Kleinmachnow (Berlin). With combined more than 140 employees, the Glycotope Group now has grown to one of the largest Biotech organisations in Germany. Glycotope´s product portfolio now encompasses a variety of antibodies and non-antibody biologics, 3 of which are currently undergoing clinical trials. The pipeline includes both new antibodies for tumor therapy (e. g. PankoMab) as well as significantly improved versions of already marketed protein therapeutics (BioBetters).

Glycotope´s underlying GlycoExpress™ technology of human cell lines facilitates the optimization of previously disregarded carbohydrate structures found on protein-based drugs (glycosylation). Thus biologics developed in GlycoExpress™ receive a fully human and optimized glycosylation, leading to a largely improved activity, an elongated half-life time and reduced immunogenicity and hence important therapeutic benefits for a significantly increased number of patients.

Contact:

Glycotope GmbH
Dr. Franzpeter Bracht, CFO & CBO
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel. +49 (0)30 94 89-2600
Fax: +49 (0)30 94 89-2609
franzpeter.bracht@glycotope.com

Glycotope Biotechnology GmbH
Dr. Jens Pohl, COO
Czerny-Ring 22
69115 Heidelberg
Germany

Tel. +49 (0)6221 9105-15
Fax: +49 (0)6221 9105-10
j.pohl@glycotope-bt.com

GLYCOTOPE was founded in 2001 by the biologist and biochemist Dr. Steffen Goletz and seed phase investor Eckert Consult Strategieberatung und Kapitalbeteiligungsgesellschaft mbH. The company operates on glycosylation structures on proteins, a relatively young sector in biotechnology. Its proprietary technology for optimization of glycosylation structures on proteins and biopharmaceuticals production permits making existing and new drugs more effective and tolerable in the human body, which is of considerable economic importance for new as well as improved versions of protein-based drugs (2^nd generation biopharmaceuticals).

The GLYCOTOPE GmbH product range features a number of antibodies and other proteins. They include both proprietary antibodies for tumour therapy (PankoMab, KaroMab) and significantly improved versions (2nd generation) of antibodies and other therapeutic proteins already on the market. The innovative company’s base technology supports the development of new active substances and marked improvement of the glycosylation structures and optimization of their effectiveness.

„The fresh capital helps us improve our financial resources dramatically, while also bringing us a strong and experienced partner. This will enable us to accelerate the development of our projects considerably and expand our glycosylation technology platform,“ said the management team comprising Dr. Steffen Goletz, Dr. Franzpeter Bracht and Dr. Hans Baumeister.

Headline 1

Headline 2

Headline 3

Headline 1 grau

Headline 2 grau

Headline 3 grau

Headline 1 rot

Headline 2 rot

Headline 3 rot

Headline 1 blau

Headline 2 blau

Headline 3 blau

Headline 1 gelb

Headline 2 gelb

Headline 3 gelb

Headline 1 orange

Headline 2 orange

Headline 3 orange

Headline 1 grün

Headline 2 grün

Headline 3 grün

Headline 1 violett

Headline 2 violett

Headline 3 violett

bold
italic
untersrichen
Erzwungener Zeilenumbruch:

Erzwungener Paragraph:

Symbole
Trademark: ™
Copyright: ©
Reg. Trademark: ®

Listen

Liste

• Inhalt 1
• Inhalt 2

Nummerierte Liste

1. Inhalt 1
2. Inhalt 2

Hyperlinks
Interner Link ohne roten Pfeil zu Kategorie 3 (öffnet in gleichem Fenster)
Interner Link zu Kategorie 3 (öffnet in gleichem Fenster)
Interner Link zu Kategorie 3 (öffnet in separatem Fenster)
Externer Link zu Glycotope Biotechnology (öffnet in separatem Fenster)
info@glycotope.com

Selected Media Coverage of Glycotope

Transkript 10/2009 on Glycotope’s glycooptimization technologies (in German)

Transkript 10/2009 on Glycotope’s acquisition of Avesta’s production assets (in German)

Transkript on Glycotope

“Erfolgreich verbunden” – Tagesspiegel, 06 May 2009

“Der Zuckercode” – Arte/ZDF visit Glycotope

Press Contact

For all press related inquiries about Glycotope, please contact:

GLYCOTOPE GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany

Tel.: +49 (0) 30 9489 2633
Fax: +49 (0) 30 9489 2609

Downloads

GLYCOTOPE LOGO
GLYCOTOPE-BIOTECHNOLOGY LOGO

Scientific Publications

2010

Lin,W.-M., Karsten,U., Goletz,S., Cheng,R.-C., Cao,Y.: Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells. Virchows Arch. 456: 403-409 (2010).

Fan,X.-N., Karsten,U., Goletz,S., Cao,Y.: Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol.Res.Pract. 206: 585-589 (2010).

Karsten,U., Butschak,G., Stahn,R., Goletz,S.: A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra- and intracellular epitopes. Int.Immunopharmacol. 10: 1354-1360 (2010).

Lin,W.-M., Karsten,U., Goletz,S., Cheng,R.-C., Cao,Y.: Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int.J.Exp.Path. (online, 2010).

2009

Jeschke,U., Walzel,H., Mylonas,I., Papadopoulos,P., Shabani,N., Kuhn,C., Schulze,S., Friese,K., Karsten,U., Anz,D., Kupka,M.S.: The human endometrium expresses the glycoprotein Mucin-1 and shows positive correlation for Thomsen-Friedenreich-epitope expression and galectin-1 binding. J.Histochem.Cytochem. (2009).

Jeschke,U., Mylonas,I., Kunert-Keil,C., Stahn,R., Scholz,C., Janni,W., Kuhn,C., Schröder,E., Mayr,D., Friese,K.: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem.Cell Biol. 131: 283-295 (2009).

Dian,D., Janni,W., Kuhn,C., Mayr,D., Karsten,U., Mylonas,I., Friese,K., Jeschke,U.: Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 32: 238-244 (2009).

Christensen,P.A., Danielczyk,A., Ravn,P., Larsen,M., Stahn,R., Karsten,U., Goletz,S.: Modifying antibody specificity by chain shuffling of VH/VL between antibodies with related specificities. Scand.J.Immunol. 69: 1-10 (2009).

2008

Larsen,M., Jensen,K.B., Christensen,P.A., Suarez,E., Paris,D., Sanz,L., Ravn,P., Sauce,D., Saas,P., Goletz,S., Alvarez-Vallina,L., Kristensen,P.: Functionally fused antibodies – a novel adjuvant fusion system. J. Immunol.Methods 31: 220-227 (2008).

Cao,Y., Merling,A., Karsten,U., Goletz,S., Punzel,M., Kraft,R., Butschak,G., Schwartz-Albiez,R.: Expression of CD175 (Tn), CD175s (sialosyl-Tn), and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int.J.Cancer 123: 89-99 (2008).

2007

Christensen,P.A., Danielczyk,A., Ravn,P., Stahn,R., Karsten,U., Goletz,S.: A monoclonal antibody to Lewis Y/Lewis b revealing mimicry of the histone H1 to carbohydrate structures. Scand.J.Immunol. 65: 362-367 (2007).

Ravn,P., Stahn,R., Danielczyk,A., Faulstich,D., Karsten,U., Goletz,S.: The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunol.Immunother. 56: 1345-1357 (2007).

2006

Butschak,G., Karsten,U., Schelhaas,U., Ott,H., Emmendörffer,A., Niemeyer,B., Helmholz,H., Goletz,S.: Detection, isolation and partial characterization of an immunostimulating glycoprotein from Rhodococcus fascians. Internat.Immunopharmacol. 6: 1441-1450 (2006).

Jeschke,U., Kuhn,C., Mylonas,I., Schulze,S., Friese,K., Mayr,D., Speer,R., Briese,V., Richter,D.-U., Haase,M., Karsten,U.: Development and characterization of monoclonal antibodies for the immunohistochemical detection of glycodelin A in decidual, endometrial and gynaecological tumour tissues. Histopathology 48: 394-406 (2006).

Danielczyk,A., Stahn,R., Faulstich,D., Löffler,A., Märten,A., Karsten,U., Goletz,S.: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol.Immunother. 55: 1337-1347 (2006).

2005

Stahn,R., Goletz,S., Stahn,R., Wilmanowski,R., Wang,X., Briese,V., Friese,K., Jeschke,U.: Human chorionic gonadotropin (hCG) as inhibitor of E-selectin-mediated cell adhesion. Anticancer Res. 25: 1811-1816 (2005).

Karsten,U., von Mensdorff-Pouilly,S., Goletz,S.: What makes MUC1 a tumor antigen? Tumor Biol. 26: 217-220 (2005).

2004

Zeisig,R., Stahn,R., Wenzel,K., Behrens,D., Fichtner,I.: Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro.Biochim.Biophys.Acta 28: 31-40 (2004).

Ravn,P., Danielczyk,A., Jensen,K.B., Kristensen,P., Christensen,P.A., Larsen,M., Karsten,U., Goletz,S.: Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. J.Mol.Biol. 343: 985-996 (2004).

Christensen,P.A., Danielczyk,A., Stahn,R., Goletz,S.: Simple separation of DNA in antibody purification. In: Protein Expression and Purification 37: 468-471 (2004).

Karsten,U., Serttas,N., Paulsen,H., Danielczyk,A., Goletz,S.: Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 14: 681-692 (2004).

2003

Jeschke,U., Wang,X., Briese,V., Friese,K., Stahn,R.: Glycodelin and amniotic fluid transferrin as inhibitors of E-selectin-mediated cell adhesion. Histochem.Cell Biol. 119: 345-354 (2003).

Goletz,S., Cao,Y., Danielczyk,A., Ravn,P., Schöber,U., Karsten,U.: Thomsen-Friedenreich antigen: the “hidden” tumour antigen. Adv.Exp.Med.Biol., Vol.535, Glycobiology and Medicine (ed. Axford,J.S.), Kluwer Academic/Plenum Publishers, New York, pp.147-162 (2003).

2002

Goletz,S., Christensen,P.A., Kristensen,P., Blohm,D., Tomlinson,I., Winter,G., Karsten,U.: Selection of large diversities of antiidiotypic antibody fragments by phage display. J.Mol.Biol. 315: 1087-1097 (2002).

Karsten,U.: CD175 Workshop Panel report. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 201-202 (2002).

Karsten,U.: CD176 Workshop Panel report. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 202-203 (2002).

Cao,Y., Karsten,U., Schwartz-Albiez,R.: Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukaemia cells. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 204-205 (2002).

Butschak,G., Karsten,U.: Isolation and characterization of Thomsen-Friedenreich-specific antibodies from human serum. Tumor Biol. 23: 113-122 (2002).

Other Articles

2010

Baumeister H, Goletz S.: A Matter of Cell Line Development. In: European BioPharmaceutical Review 2010: Apr. Download

2009

Baumeister H, Goletz S.: Novel Glycosylation Technologies for the Development of Biosimilars and Biobetters. In: Innovations In Pharmaceutical Technology 2009: Dec. Download

2005

Baumeister H, Goletz S.: GlycoExpress: A novel expression system for the optimal glycosylation of biotherapeutics. In: Speciality Chemicals Magazine 2005: Vol 25.

Baumeister H, Schoeber U, Schlangstedt M, Stahn R, Goletz S.: A novel human expression system for generating glycoprotein with higher activity, fully human glycosylation, and optimised sialylation. In: BioProcessing Journal 2005: Vol 4. Download

Baumeister H, Goletz S.: Voll funktionsfähige humane dendritische Zelllinie. In: Laborwelt 2005: Vol 6. Download

2004

Goletz S, Baumeister H.: Opportunities with NEMOD & GLYCOTOPE. In: R&D FOCUS drugnews 2004: Vol 13.

Baumeister H.: GlycoEngineering – a Technology for Production of Glycoproteins. In: BioTOPics 2004: Vol 24. Download

Baumeister H, Goletz S.. A novel technology for the production of highly active therapeutic proteins. In: DrugPlus international 2004: Vol 03. Download

Terms and Conditions Glycotope GmbH:

Deutsche Version
English Version

Terms and Conditions Glycotope Biotechnology GmbH:

Deutsche Version
English Version

Glycotope is maintaining these outreaching business relations and is pleased and privileged to name a few of our business clients:

The Berlin GLYCOTOPE Team in 2010

The Heidelberg GLYCOTOPE-Biotechnology Team

The company facilities comprises about 3500 sqm in total which divide into:

• 1500 sqm biotechnology production
• 300 sqm R&D lab space
• 200 sqm QC labs
• 700 sqm storage rooms
• 200 sqm administration

According to the German Drug Law (AMG) Glycotope Biotechnology is inspected by the State Authorities. Glycotope Biotechnology is certified according to ISO 9001:2000 since 2001.The facilities are also approved according to the corresponding German laws for Gene Technology (GenTG), Control of Epidemics (IfSG, BioStoffV) and Protection against Radiation (StrlSchV).

Herceptin has been approved for the treatment of HER2 positive breast cancer and HER2 positive stomach cancer.

Glycotope´s TrasGEX has been glycooptimized in Glycotope´s fully human development platform GlycoExpressTM. As a result, TrasGEX shows a significantly improved ADCC-activity, in particular among all allotypes of the FcγIIIa-receptor mediating the ADCC, promising a significantly better therapeutic outcome for all patients eligible for treatment with Trastuzumab. Simultaneously, the fully human nature of Tras-GEX’ host cell lines avoids the common immunogenic reactions against host-derived non-human components.

TrasGEX has entered clinical phase I in March 2011.

For applications and questions on both openings at GLYCOTOPE (Berlin) and GLYCOTOPE-BIOTECHNOLOGY (Heidelberg) please contact:

GLYCOTOPE GmbH
Bettina Eichhöfer
Robert-Roessle-Str. 10
13125 Berlin

Tel.: +49-30-9489 2604
Fax : +49-30-9489 2609
E-mail:

Zur Zeit suchen wir:

• ELISA in all formats
• SDS-PAGE, IEF, Western Blot
• Peptide mapping
• Immunocyto- and histochemical staining
• Cell binding and scatchard analysis
• Binding analysis by Biacore®
• Analysis of the formation of aggregates by SEC and dynamic light scattering (Zetasizer Nano)
  
• Antibody isotype characterization
• Analysis of glycosylation
• FACS-based assays

For analytical services of our GMP facility please visit Glycotope Biotechnology.

Starting with eight employees to develop the GlycoExpress™ technology, today the company employs more than 140 people at two sites in Berlin and Heidelberg and by applying the GlycoExpress™ technology significantly widend its focus from a pure technology provider to the development of proprietary and strongly improved 2nd generation biotherapeutics. Part of this process was the acquisition of all assets of the Nemod Biotherapeutics Co. KG in 2007.

GLYCOTOPE BIOTECHNOLOGY, located in Heidelberg, comprises the former biotechnological activities of Orpegen Pharma, which Glycotope acquired in 2008. Glycotope Biotechnology allows Glycotope to produce its glycooptimized biotherapeutics under GMP conditions.

Based on Glycotope’s technology portfolio and business concepts, the participation of Hexal founders Thomas & Andreas Struengmann in 2007 constituted one of the largest biotech investments in Germany.

Glycotope is located in Berlin at the place of its foundation on the Biotech-Campus Buch in the Northeast of Berlin.

For scientific publications & articles, please visit the Scientific Publications section.
Media coverage & information on Glycotope can be found under Media Coverage.

Glycotope GmbH
Robert-Roessle-Strasse 10
13125 Berlin
Germany

T: +49 (0)30 9489-2604
F: +49 (0)30 9489-2609

Court of Registration:
Berlin HRB 79054
Amtsgericht Berlin-Charlottenburg

USt.-ID: DE217650913

Management:

Steffen Goletz, Ph.D.,
CEO / CSO

Franzpeter Bracht, Ph.D.,
CFO / CBO

Website generated by:

BRAUCH MEDIA
www.brauchmedia.com

Wolfgang Scheible Design & Werbung
www.grafik-designer.com

Photos:

Maj Britt Hansen
Esther Suave
fotolia
iStockphoto

Disclaimer

This website provides general information about our company, its products and services. Due to the nature of our products and services they may be subject to changes and some of those are provided only regionally or with a regional difference also reflected by its customized nature. Our webpage and its contents does not purport to convey medical advice, and on no account is it a substitute for a consultation with a medical practitioner. The attention of users of our products is drawn to the directions for use accompanying the product.

All content is prepared with the greatest possible care and is subject to constant updates and additions. We accept no liability for any errors arising, nor for the continuing relevance of the content to the current situation. We accept no liability for third-party content quoted by us on this website or to which we refer through hyperlinks.

The content of this website is intended for users within the European Union and has been prepared by us under the provisions of German law. We do not guarantee the legality of this website under the jurisdiction of other countries.

All copyright for the content of this website is vested in our company. The application of this material for commercial purposes is only permitted with our prior authorization.

• Pipeline
• PankoMab-GEX™
• CetuGEX™
• TrasGEX™
• FSH-GEX™
• Technologies
• GlycoExpress™ and GlycoOptimization
• GlycoBodies
• GlycoProcess
• Antibody Technologies
• Contract Research
• GlycoOptimization
• Cell Line Development
• Preclinical Evaluation
• Process Development
• GMP Production
• R&D Products
• Analytical Services
• Protein Analytics
• Bioactivity and Cellular Assays
• Host Cell Contaminants
• Immunomonitoring
• Manufacturing Services
• Upstream Processing / Cell Culture
• Downstream Processing / Protein Purification
• Fill and Finish
• Cell Banking
• Immunodiagnostics
• Diagnostics/ Research Reagents
• MHC Class I Tetramer Reagents
• About us
• History
• Facilities
• References
• Investors
• Management
• Team
• News & Media
• News
• Scientific Publications
• Media Coverage
• Downloads
• Events & Conferences
• Contact
• General Inquiries
• Terms of Business
• Business Development
• Directions
• Jobs
• Imprint
]]> http://www.glycotope.com/sitemap/feed 0 http://www.glycotope.com/about http://www.glycotope.com/about#comments Sat, 12 Feb 2011 08:35:08 +0000 admin http://www.glycotope.com/?p=15 The Glycotope Group consists of Glycotope GmbH, based in Berlin, Germany and its 100% subsidiary, Glycotope Biotechnology, based in Heidelberg, Germany. With more than 150 employees, Glycotope represents one of the largest Biotech companies in Germany.

Together, the companies are active in the development of proprietary biopharmaceuticals based on Glycotope´s GlycoExpress technology for the improvement of protein therapeutics.

Simultaneously, we perform a wide range of contract research and manufacturing services . While Glycotope Biotechnology is for now more than 25 years a reknown partner of the pharmaceutical industry for GMP production and analytics of biologics, Glycotope is conducting extensive customer projects in drug development, most notably development of Biosimilars and improved 2^nd generation therapeutics, similar to its own pipeline.

Download CorporateProfile

]]> http://www.glycotope.com/about/feed 0 http://www.glycotope.com/welcome http://www.glycotope.com/welcome#comments Fri, 11 Feb 2011 19:44:50 +0000 admin http://www.glycotope.com/?p=1

GLYCOTOPE is a global leader in optimizing the glycosylation of biopharmaceuticals

GlycoExpress is one of the broadest platform technologies for the development and production of glycosylated proteins.

A clinical pipeline of 4 glycooptimized BioBetters and NBEs underlines GLYCOTOPE´s and its manufacturing arm GLYCOTOPE BIOTECHNOLOGY´s competence to contribute significant improvements to healthcare.

]]> http://www.glycotope.com/welcome/feed 0 http://www.glycotope.com/business-development http://www.glycotope.com/business-development#comments Wed, 09 Feb 2011 10:46:36 +0000 admin http://www.glycotope.com/?p=758 GLYCOTOPE is currently running a structured partnering process for several of its late-stage assets.
For further information and requests, please contact:

Dr. Franzpeter Bracht
Chief Business Officier

Georg Adelberger
Business Development Manager

 

GLYCOTOPE GmbH

Robert-Roessle-Str.10
13125 Berlin
Germany

phone:+49 (30) 9489 2633
fax:+49 (30) 9489 2609



]]> http://www.glycotope.com/business-development/feed 0 http://www.glycotope.com/news1-2 http://www.glycotope.com/news1-2#comments Tue, 14 Dec 2010 10:15:10 +0000 admin http://www.glycotope.com/?p=19 Berlin, Germany – December 14, 2010

Glycotope GmbH, a leading glycobiology company, has won the innovation award 2010 jointly presented by the German states of Berlin and Brandenburg in recognition of the company’s GlycoExpress™ technology platform. GlycoExpress™ combines a very efficient improvement of the activities and side effects of a broad range of protein biopharmaceuticals with the suitability for a much broader patient population and a very high productivity. Currently four therapeutic proteins (3 antibodies) have been produced under GMP two of which are currently tested in clinical trials.

“We are highly delighted”, says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope GmbH. “After receiving the STEP award 2010, winning another prestigious prize within short time is an important recognition of our scientific and corporate advances we have accomplished over the last years”.

With close to 70 employees just at the Biotech-campus in Berlin-Buch, Glycotope has developed into an outstanding representative of the Biotech region Berlin-Brandenburg.

About Glycotope GmbH and the GlycoExpress™ technology

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, the broadest, most potent and validated GlycoOptimization technology for improvement of the vast majority of antibodies & protein biopharmaceuticals is superior in productivity and quality to current production systems. GlycoExpress™ allows to make existing and new biopharmaceutical drugs more effective with less side effects and a suitability for a much broader patient population, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development such as lead optimization, preclinical and process development, GMP production down to the clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters. Two of these products have initiated the clinic since 2009, with two more to follow in the first half of 2011.

The Award
The prestigious innovation prize is jointly awarded by the German states of Berlin and Brandenburg in public-private-partnership with corporate partners of the capital region. The award focuses on supporting businesses and innovators in the region, recognizing outstanding innovation and aimed at linking research, development and corporations in order to stimulate innovation in future growth sectors like Biotech/Medtech/Pharma, Energy, IT/TelCom/Media, optics and transportation. The price is awarded every year in December to a maximum of 5 winners and valued at 10.000 €.


Contact:
Glycotope GmbH
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609
Web: www.glycotope.com
E-Mail: news@glycotope.com

]]> http://www.glycotope.com/news1-2/feed 0 http://www.glycotope.com/glycotope-winner-at-step-award-2010 http://www.glycotope.com/glycotope-winner-at-step-award-2010#comments Wed, 17 Nov 2010 10:17:15 +0000 admin http://www.glycotope.com/?p=21 Berlin, Germany – November 17, 2010

Glycotope GmbH, a leading glycobiology company, has yesterday been awarded with the 2010 STEP-Award for financing. Glycotope was selected for its strategically aligned and long-term funding concept. A delighted CFO Dr. Franzpeter Bracht stated: “In addition to our outstanding technology, from the beginning we have put great emphasis on a balanced mix of revenues and investments.” “The extraordinary financial commitment by Drs. Thomas and Andreas Strüngmann has been of tremendous help though and secured the long term growth of our company, based on our outstanding technology the basis for our largely improved biopharmaceuticals developed by our CEO, CSO and founder Dr. Steffen Goletz” states Dr. Hans Baumeister, COO. Even ahead of entering pipeline- and technology-related licensing agreements, Glycotope has thus been able to cover a large proportion of its expenditures via its contract research, manufacturing and diagnostics business

About Glycotope GmbH

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, the internationally broadest, most potent and validated GlycoOptimization technology for improvement of the vast majority of antibodies & protein biopharmaceuticals and is superior in productivity and quality to current production systems.GlycoExpress™ allows to make existing and new biopharmaceutical drugs more effective and tolerable in the human body and suitable for a broader patient population, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development such as lead optimization, preclinical and process development, GMP production down to the clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins, so called Biobetters.

About the STEP-Award

In its fifth round more than 100 companies from Germany, Austria and Switzerland applied for the STEP Award initiated by the F.A.Z.-Institute and Infraserv Höchst. The idea of the initiators is to assist innovative and growing companies in their next “STEP” to the market and to trigger an important impulse for their successful development. With more than 500 applications over the last years from companies that are active in the prospering fields of Chemistry, Pharma, Life Science, Bio-/Nanotechnology, Medical Technology and Greentech the value of the STEP Award has been widely accepted.

Contact:

Glycotope GmbH
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609
Web: www.glycotope.com
eMail: news@glycotope.com

]]> http://www.glycotope.com/glycotope-winner-at-step-award-2010/feed 0 http://www.glycotope.com/glycotope-presents-approved-glycoexpress-technology-at-bio-europe-2010 http://www.glycotope.com/glycotope-presents-approved-glycoexpress-technology-at-bio-europe-2010#comments Fri, 12 Nov 2010 13:58:55 +0000 admin http://www.glycotope.com/?p=1155 Berlin, Germany – November 12, 2010

Glycotope GmbH, a leading glycobiology company, will present recent advances with its GlycoExpress^TM technology of novel human cell lines during the upcoming BIO-Europe in Munich. With two of its glycooptimized antibodies produced by GlycoExpress™ and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress™ for production of biotherapeutics. This strongly validates this innovative technology for future development and production of therapeutic proteins.  The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority. All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).

About GlycoExpress™

GlycoExpress™ is based on a tool box of glycoengineered human cell lines for glycooptimization and high yield production of glycooptimized biotherapeutics, such as antibodies. The antibody’s fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. Glycooptimization with GlycoExpress™ is not limited to antibodies but suitable for the majority of therapeutically relevant proteins. The technology platform is available for cooperation partners via service & license agreements.

About Glycotope GmbH

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, one of the company’s proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all phases in drug development from lead discovery, preclinical development, GMP production down to the clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other already marketed therapeutic proteins.

Contact:

Glycotope GmbH
Dr. Franzpeter Bracht
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609
Web: www.glycotope.com
eMail: news@glycotope.com

]]> http://www.glycotope.com/glycotope-presents-approved-glycoexpress-technology-at-bio-europe-2010/feed 0 http://www.glycotope.com/interview-with-ceo-cso-dr-steffen-goletz http://www.glycotope.com/interview-with-ceo-cso-dr-steffen-goletz#comments Mon, 20 Sep 2010 13:06:21 +0000 admin http://www.glycotope.com/?p=1157 In a recent interview, Dr. Steffen Goletz, Founder, CEO & CSO of Glycotope talks about recent and future developments at Glycotope (German): Read the interview
]]> http://www.glycotope.com/interview-with-ceo-cso-dr-steffen-goletz/feed 0 http://www.glycotope.com/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetugex%e2%84%a2-and-enrolls-first-patients-in-clinical-trial http://www.glycotope.com/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetugex%e2%84%a2-and-enrolls-first-patients-in-clinical-trial#comments Wed, 04 Aug 2010 13:07:45 +0000 admin http://www.glycotope.com/?p=1160 Berlin, Germany – August 4, 2010

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. “For Glycotope, the approval of CetuGEX™, our second antibody in the clinic, represents another important milestone,” says Steffen Goletz, CEO & CSO of Glycotope. “CetuGEX™ is our first in a series of next generation biotherapeutic products. We expect that the strong advantages in various product aspects we have seen in preclinical studies will manifest in a clear clinical superiority compared to the currently marketed product. In addition, the second cell line of Glycotope´s glycooptimization platform GlycoExpress™ based on human cell lines has now been approved, meeting our ambitions for quality and speed.” CetuGEX™ was the second antibody in clinical stage produced in Glycotope´s own GMP facility in Heidelberg.

About CetuGEX™

CetuGEX™ is an improved version of a currently marketed anti-EGFR antibody which has been approved for the treatment of colorectal and head & neck cancers. The antibody’s fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. This was achieved with Glycotope´s proprietary technology platform GlycoExpress™, a screening and high yield production system of glycoengineered human cell lines.

About Glycotope GmbH

GLYCOTOPE, founded in 2001, focuses on the optimization and humanization of therapeutically relevant carbohydrate structures known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. GlycoExpress™, one of the company’s proprietary technologies, allows making existing and new biopharmaceutical drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. Glycotope evolved into a leading integrated glycobiology company, covering all steps from lead discovery, preclinical development, GMP production and clinical development. Glycotope´s most advanced pipeline includes antibodies against novel targets for cancer therapy (e.g. GT-MAB 2.5-GEX™) and significantly improved versions of antibodies as well as other marketed therapeutic proteins.

Contact:

Glycotope GmbH
Dr. Franzpeter Bracht
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609
Web: www.glycotope.com
eMail: news@glycotope.com




]]> http://www.glycotope.com/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetugex%e2%84%a2-and-enrolls-first-patients-in-clinical-trial/feed 0 http://www.glycotope.com/glycotope-moves-to-new-premises-2 http://www.glycotope.com/glycotope-moves-to-new-premises-2#comments Fri, 11 Dec 2009 11:58:00 +0000 admin http://www.glycotope.com/?p=1045 Berlin, December 10th, 2009 – Following it’s outstanding growth in the past 18 months, raising the headcount from 20 to 70 employees, GLYCOTOPE has now consolidated it’s dispersed teams and expanded it’s office and laboratory space in a new location on the Biotech Campus Berlin Buch.

Instead of in the complexes D79 and D80, GLYCOTOPE now resides within the 1st and 2nd floor of “Arnold-Graffi-Haus” D85 .



Our contact details remain unchanged:

GLYCOTOPE GmbH
Robert-Roessle-Str. 10
13125 BERLIN
Germany

Tel.: +49-30-9489-2600
Fax: +49-30-9489-2609
Web: www.glycotope.com
eMail: info@glycotope.com

]]> http://www.glycotope.com/glycotope-moves-to-new-premises-2/feed 0 http://www.glycotope.com/glycotope-receives-regulatory-approval-for-glycoexpress-technology-and-initiates-first-clinical-trial-with-lead-antibody-gt-mab-2-5-gex http://www.glycotope.com/glycotope-receives-regulatory-approval-for-glycoexpress-technology-and-initiates-first-clinical-trial-with-lead-antibody-gt-mab-2-5-gex#comments Mon, 23 Nov 2009 13:47:53 +0000 admin http://www.glycotope.com/?p=1142 Berlin – November 23rd, 2009

Glycotope GmbH, a leading German Biotech company, has received regulatory approval by Germany and Italian regulatory authorities for a Phase I study of Glycotope´s lead antibody GT-MAB 2.5-GEX^TM for the treatment of various solid cancers. The approvals further underline the suitability of Glycotope´s proprietary GlycoExpress^TM technology for the improvement, glycooptimization and high yield production of therapeutic proteins for the use in humans.

“The approval of GT-MAB 2.5-GEX as well as the regulatory approval of the GlycoExpress production technology based on its glycoengineered human cell lines represents a significant milestone for the company” says Steffen Goletz, PhD, Founder, CEO and CSO of Glycotope. “After generating very encouraging data in pre-clinical studies, we are now looking forward to demonstrate the importance of glycosylation in the clinic by generating a substantial benefit to patients.”

The Phase I study will evaluate the safety and tolerability of GT-MAB 2.5-GEX^TM in a broad series of cancer indications.

About GT-MAB 2.5-GEX

GT-MAB 2.5-GEX^TM is a novel, exceptionally potent monoclonal antibody for the treatment of a broad variety of cancer indications. The antibody is directed against a novel tumor-specific combined carbohydrate-protein epitope present in a large number of patients of various cancers. GT-MAB 2.5-GEX^TM shows three highly effective key modes of anti-tumor action: ADCC, phagocytosis and induction of apoptosis with an exceptionally high and specific tumor accumulation and tumor killing already at doses as low as 0.5 mg/kg.

The antibody’s fully human glycosylation is optimized to yield a largely improved ADCC activity, bioavailability and no non-human immunogenic carbohydrate structures. This was achieved by Glycotope´s proprietary technology platform GlycoExpress^TM, a screening and high yield production system of glycoengineered human cell-lines that allows significant enhancement of therapeutic potency by optimizing a protein’s glycosylation in various aspects.

About Glycotope GmbH

GLYCOTOPE was founded in 2001 and focuses on the improvement and humanization of glycosylation structures on proteins, a comparatively new field in biotechnology. GlycoExpress^TM, the company’s proprietary technology permits making existing and new drugs more effective and tolerable in the human body, which is of considerable medical as well as economic importance. The current product range currently includes both proprietary antibodies for cancer therapy (e.g. GT-MAB 2.5-GEX^TM) and significantly improved versions (2nd generation) of antibodies and other therapeutic proteins already on the market.

]]> http://www.glycotope.com/glycotope-receives-regulatory-approval-for-glycoexpress-technology-and-initiates-first-clinical-trial-with-lead-antibody-gt-mab-2-5-gex/feed 0 http://www.glycotope.com/glycotope-biotechnology-launches-cmv-tetramer-kit http://www.glycotope.com/glycotope-biotechnology-launches-cmv-tetramer-kit#comments Mon, 27 Jul 2009 12:50:54 +0000 admin http://www.glycotope.com/?p=1145 Heidelberg, 24 July 2009 – Progressive CMV infections pose a major threat to transplant recipients. CD8 T cells are considered as the major player to control CMV viremia and sufficient levels of CMV-specific CD8 T cells are found to protect against CMV disease.

Current assays based on PCR and antigen-detection are capable of analysing the viral burden and detect a CMV reactivation, however, any immunoreactivtity against CMV cannot be assessed.

Glyctope Biotechnology has developed a ready-to-use CMV-Tetramer Test that provides for the first time a possibility to quantify the number of CMV-specific CD8 T cells, thus helping the clinician to assess patients with high risk to develop CMV disease.

Main assay features:

• Standardized and CE-certified ready-to-use staining kit (performance time about 2h)
• Direct analysis of whole blood
• Highly specific and sensitive detection of CMV-specific CD8 T cells due to the use of tetramers
• Combination of well characterized CMV peptides that cover about 80% of HLA types
• Determination of the absolute numbers of CMV-specific CD8 T cells and the percentage CD4 and CD8 T cells.

Economic Benefits:

• Kit contains all necessary compounds including a negative control
• Easy and economic procedure based on flow cytometry achieving quick results at low costs with high accuracy and precision

Expected benefits of monitoring the CMV-specific CD8 T cell number:

• The Test allows the clinician to assess the immune status of the patient to combat with the progressive viral infection.
• It helps the clinician to reduce the amount of toxic and expensive antiviral drugs in the treatment

References:
1) Gratama & Cornelissen, Clin. Appl. Immun.Rev. 2001
2) Moss & Khan, Hum. Immun. 2004
3) Cwynarski et al. Blood 2001
4) Gratama et al. Blood 2001
5) Gratama et al., Cytometry B Clin. Cytom. 2008

For further information, please visit the CMV-Tetramer section on the website of Glycotope Biotechnology.

]]> http://www.glycotope.com/glycotope-biotechnology-launches-cmv-tetramer-kit/feed 0 http://www.glycotope.com/glycotope-service-portfolio-expanded-with-aseptic-fill-finish http://www.glycotope.com/glycotope-service-portfolio-expanded-with-aseptic-fill-finish#comments Fri, 17 Jul 2009 12:52:58 +0000 admin http://www.glycotope.com/?p=1149 Heidelberg, 05 June 2009 – GLYCOTOPE BIOTECHNOLOGY, an established CMO equipped with state-of-the-art technologies and more than 25 years of experiences in GMP production of biotherapeutics announces the approval for Fill & Finish of clinical grade material. Since then, the company has successfully completed five Fill & Finish projects for different customers.

The approval allows GLYCOTOPE BIOTECHNOLOGY to provide its customers with a complete service “from the gene to the drug” at highest technological level. As a unique benefit, we offer our clients the use of our toolbox of human, glycoengineered cell lines (GlycoExpress™) for glycooptimization of biopharmaceuticals. Our knowhow in controlling glycosylation patterns of antibodies and other therapeutic proteins during cell line development and establishment of production processes is of pivotal importance not only in the development of glycooptimized biotherapeutics but also of biosimilars that need to have the same characteristics as the originator product.

]]> http://www.glycotope.com/glycotope-service-portfolio-expanded-with-aseptic-fill-finish/feed 0 http://www.glycotope.com/glycotope-gmbh-acquires-gmp-production-site-of-orpegen-gmbh http://www.glycotope.com/glycotope-gmbh-acquires-gmp-production-site-of-orpegen-gmbh#comments Thu, 24 Jul 2008 10:22:52 +0000 admin http://www.glycotope.com/?p=674 Berlin, Heidelberg, 24 July 2008.
Glycotope Biotechnology GmbH, a fully consolidated subsidiary of Berlin-
based Glycotope GmbH, has acquired the biopharmaceutical production
facility and diagnostic business of Orpegen Pharma GmbH, which has been
based in Heidelberg for over two decades.

“With the acquisition of the production capacities in four separate GMP suites, we are creating excellent basic conditions for the further development of our glycosylation technology, with which we are improving both our own and other products already on the market,” explains Steffen Goletz, founder and scientific head of the company. In addition, GLYCOTOPE now operates independently in the GMP-based production of its development candidates. The company already has its first manufacturing licenses under the Medicines Act (AMG).

“We see this as an important step in optimising the value creation chain for the
strategic positioning of our associate company,” says Helmut Jeggle, representative of Athos GmbH. The purchase was financed and co-initiated through another capital increase signed by investor Jossa Arznei GmbH. Behind Jossa stands Athos GmbH which, as the family office of the Strüngmann brothers, now makes its know-how available to select biotech companies and embarks

“In order to further expand the capital-intensive, pioneeringbiotechnology position at the Heidelberg production site with the glycoprotein know-how developed at ORPEGEN, the transfer of biopharmaceutical assets to the financially stronger GLYCOTOPE was the logical, appropriate thing to do,” says Christian Birr, managing partner of ORPEGEN Pharma, which he founded in 1982. The development and production of peptide agents, amino acid derivatives and small molecules will be independently continued by the former Chemistry division at the site, while co- shareholder Hightech Beteiligungen GmbH & Co. KG will withdraw from its involvement in ORPEGEN Pharma.

About Glycotope GmbH
The product range of GLYCOTOPE GmbH covers various antibodies and other biopharmaceuticals. This includes both its own antibodies for tumour therapy (PankoMab, KaroMab) and much improved versions (2^nd generation) of antibodies already available on the market or other proteins used in therapy.

The innovative character of GLYCOTOPE’s basic technology “GlycoExpress™”, which is based on glyco-optimised human high-production cell lines, lies in the development of new drug compounds as well as in the humanisation and optimisation of glycosylation structures and hence the associated enormousincrease in the effectiveness of so-called “2^nd generation” agents.

]]> http://www.glycotope.com/glycotope-gmbh-acquires-gmp-production-site-of-orpegen-gmbh/feed 0